Researchers at the Broad Institute of MIT and Harvard and Princeton University have developed a CRISPR-based technology that can rapidly differentiate between omicron, delta, and other COVID-19 variants, as well as other respiratory viruses including flu. The team used the method, known as mCARMEN, during the beginning of the omicron surge in December 2021 to get a provisional look at the rising prevalence of the variant in Massachusetts. Based on those results, the Massachusetts Department of Public Health (MDPH) shared this information with hospitals in the state to help guide treatment options for COVID-19 patients.